Boehringer Ingelheim International GmbH

General information
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate
Germany

Contact person: Harro Ten Wolde, Head of Global Media Relations
Company main phone: +49 (6132) 770
Company main fax:  +49 (6132) 720
Website:  https://www.boehringer-ingelheim.com
Year founded:1885
Source of foundation:Independent foundation
Name of foundation source:Founded by Mr. Albert Boehringer
No. of employees: Worldwide:  53500
Corporate description / mission:
Boehringer Ingelheim International GmbH is a research-driven biopharmaceutical company focusing on human and animal health globally. The company operates primarily across three business areas: Human Pharma, which covers conditions like cardiometabolic, respiratory, oncology, and central nervous system diseases; Animal Health, offering products like vaccines and parasiticides for pets and livestock; and Biopharmaceutical Contract Manufacturing.
State of ownership: Private / independent
Headquarters: HQ: Yes
Remarks on ownership / listings
Boehringer Ingelheim GmbH was formerly known as Boehringer Ingelheim Zentrale GmbH and changed its name to Boehringer Ingelheim GmbH in 1989.
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Anti-infectives
  • Antibodies
  • Gene therapy
  • Nucleic acid drugs
  • Peptides
  • Proteins
  • Vaccines
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • External causes of morbidity and mortality / traumatology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Mental and behavioural disorders / psychiatry /psychology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • In-licensing
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Distribution:
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:34
Phase I:43
Phase II:28
Phase III:15
On the market:16
Description of products:
Survodutide
Spesolimab, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Re-Vana Therapeutics
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.
© 2025 Biotechgate by Venture Valuation
X